临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
Journal of Clinical Psychosomatic Diseases
2015年
5期
36-38
,共3页
躯体形式障碍%心身疾病%度洛西汀%米氮平%汉密顿焦虑量表%副反应量表
軀體形式障礙%心身疾病%度洛西汀%米氮平%漢密頓焦慮量錶%副反應量錶
구체형식장애%심신질병%도락서정%미담평%한밀돈초필량표%부반응량표
SD%psychosomatic disease%duloxetine%mirtazapine%HAM A%TESS
目的:探讨度洛西汀与米氮平治疗躯体形式障碍的临床疗效和安全性。方法将80例躯体形式障碍患者随机分为两组,每组40例,观察组口服度洛西汀治疗,对照组口服米氮平治疗,观察8周。采用汉密顿焦虑量表评定临床疗效,副反应量表评定不良反应。结果治疗后两组汉密顿焦虑量表总分均较治疗前呈持续性下降(P<0.01),同期观察组较对照组下降更显著(P<0.05或0.01);治疗8周末观察组显效率为85.0%,对照组为62.5%,观察组显著高于对照组(χ2=5.23,P<0.05)。两组不良反应均较轻微,治疗各时点两组副反应量表评分比较差异无显著性(P>0.05)。结论度洛西汀治疗躯体化障碍起效更快,疗效显著,安全性高,依从性好,优于米氮平治疗。
目的:探討度洛西汀與米氮平治療軀體形式障礙的臨床療效和安全性。方法將80例軀體形式障礙患者隨機分為兩組,每組40例,觀察組口服度洛西汀治療,對照組口服米氮平治療,觀察8週。採用漢密頓焦慮量錶評定臨床療效,副反應量錶評定不良反應。結果治療後兩組漢密頓焦慮量錶總分均較治療前呈持續性下降(P<0.01),同期觀察組較對照組下降更顯著(P<0.05或0.01);治療8週末觀察組顯效率為85.0%,對照組為62.5%,觀察組顯著高于對照組(χ2=5.23,P<0.05)。兩組不良反應均較輕微,治療各時點兩組副反應量錶評分比較差異無顯著性(P>0.05)。結論度洛西汀治療軀體化障礙起效更快,療效顯著,安全性高,依從性好,優于米氮平治療。
목적:탐토도락서정여미담평치료구체형식장애적림상료효화안전성。방법장80례구체형식장애환자수궤분위량조,매조40례,관찰조구복도락서정치료,대조조구복미담평치료,관찰8주。채용한밀돈초필량표평정림상료효,부반응량표평정불량반응。결과치료후량조한밀돈초필량표총분균교치료전정지속성하강(P<0.01),동기관찰조교대조조하강경현저(P<0.05혹0.01);치료8주말관찰조현효솔위85.0%,대조조위62.5%,관찰조현저고우대조조(χ2=5.23,P<0.05)。량조불량반응균교경미,치료각시점량조부반응량표평분비교차이무현저성(P>0.05)。결론도락서정치료구체화장애기효경쾌,료효현저,안전성고,의종성호,우우미담평치료。
Objective To explore the efficacy and safety of duloxetine and mirtazapine in the treatment of somatoform disorder (SD) .Methods Eighty SD patients were randomly assigned to two groups of 40 ones each ,observation group took orally duloxetine and control did mirtazapine for 8 weeks .Efficacies were as‐sessed with Hamilton Anxiety Scale (HAMA) and adverse reactions with the Treatment Emergent Symp‐tom Scale (TESS) .Results After treatment the total scores of the HAMA of both groups lowered contin‐uously compared with pretreatment (P< 0 .01) ,in the corresponding period that lowered more significant‐ly in observation than in control group (P< 0 .05 or 0 .01) ;at the end of the 8th week obvious effective rate was significantly higher in observation than in control group (χ2 = 5 .23 ,P < 0 .05) .Adverse reactions of both groups were mild ,there were no significant group differences in the TESS scores at each time‐point . Conclusion Duloxetine takes effect more rapidly and has an evident effect ,higher safety and better com‐pliance compared with mirtazapine in the treatment of somatoform disorder .